Akinsanya Karen Insider Trades & Stock Holdings

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships · Schrödinger, Inc. · Latest filing Sep 17, 2026

Akinsanya Karen, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships at Schrödinger, Inc. has 1 Form 4 trade on file since Sep 17, 2026. Open-market activity: 0 purchases ($0) and 1 sale ($927.97K), net -$927.97K. Latest filing: disposed of 31.60K shares of $SDGR on Sep 17, 2026 at $29.37.

Trades on file

1

Open-market bought

$0

Open-market sold

$927.97K

Net open-market

-$927.97K

Latest filing

Sep 17, 2026

All insider trades by Akinsanya Karen

Date	Ticker	Type	Shares	Price	Value	Owned after	ΔOwn	1W	1M	6M	Role	Filing	Story
Sep 17, 2026	$SDGR	Sell (Open-market sale) 10b5-1	31.60K	$29.37	$927.97K						President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships		—

"Buy" means shares acquired on the Form 4 (including grants and option exercises); "Sell" means shares disposed. 1W / 1M / 6M = how the stock moved after the trade.

Stocks Akinsanya Karen traded

• $SDGR

Frequently asked questions

Has Akinsanya Karen been buying or selling stock?

Akinsanya Karen has 0 open-market purchases and 1 open-market sale on file, net -$927.97K. Grants, option exercises and tax withholding are listed separately because they are not open-market trades.

What was Akinsanya Karen's latest insider trade?

disposed of 31.60K shares of $SDGR on Sep 17, 2026 at $29.37.

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.